1-5 of 5
Rolf A. Stahel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial

Ross A. Soo, Urania Dafni, Ji-Youn Han, Byoung Chul Cho, Ernest Nadal, Chong Ming Yeo, Enric Carcereny, Javier de Castro, Maria Angeles Sala, Linda Coate, Mariano Provencio, Christian Britschgi, Patrick Vagenknecht, Georgia Dimopoulou, Roswitha Kammler, Stephen P. Finn, Solange Peters, Rolf A. Stahel, for the ETOP 10-16 BOOSTER Collaborators
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (22): 5180–5191.
https://doi.org/10.1158/1078-0432.CCR-24-0932
Published: 15 November 2024
View articletitled, ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Open the PDF for ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial in another window
Includes: Supplementary data
Journal Articles

Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients

Paulino Tallón de Lara, Virginia Cecconi, Stefanie Hiltbrunner, Hideo Yagita, Martina Friess, Beata Bode, Isabelle Opitz, Bart Vrugt, Walter Weder, Paul Stolzmann, Emanuela Felley-Bosco, Rolf A. Stahel, Verena Tischler, Christian Britschgi, Davide Soldini, Maries van den Broek, Alessandra Curioni-Fontecedro
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (24): 6345–6354.
https://doi.org/10.1158/1078-0432.CCR-18-1231
Published: 13 December 2018
View articletitled, Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients
Open the PDF for Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients in another window
Includes: Supplementary data
Journal Articles

Role of Hedgehog Signaling in Malignant Pleural Mesothelioma

Yandong Shi, Ubiratan Moura, Isabelle Opitz, Alex Soltermann, Hubert Rehrauer, Svenja Thies, Walter Weder, Rolf A. Stahel, Emanuela Felley-Bosco
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4646–4656.
https://doi.org/10.1158/1078-0432.CCR-12-0599
Published: 30 August 2012
View articletitled, Role of Hedgehog Signaling in Malignant Pleural Mesothelioma
Open the PDF for Role of Hedgehog Signaling in Malignant Pleural Mesothelioma in another window
Includes: Supplementary data
Journal Articles

A Recombinant Immunotoxin Derived from a Humanized Epithelial Cell Adhesion Molecule-specific Single-Chain Antibody Fragment Has Potent and Selective Antitumor Activity

Claudio Di Paolo, Jörg Willuda, Susanne Kubetzko, Ikar Lauffer, Dominique Tschudi, Robert Waibel, Andreas Plückthun, Rolf A. Stahel, Uwe Zangemeister-Wittke
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (7): 2837–2848.
Published: 01 July 2003
View articletitled, A Recombinant Immunotoxin Derived from a Humanized Epithelial Cell Adhesion Molecule-specific Single-Chain Antibody Fragment Has Potent and Selective Antitumor Activity
Open the PDF for A Recombinant Immunotoxin Derived from a Humanized Epithelial Cell Adhesion Molecule-specific Single-Chain Antibody Fragment Has Potent and Selective Antitumor Activity in another window
Journal Articles

A Novel Bispecific Antisense Oligonucleotide Inhibiting Both bcl-2 and bcl-xL Expression Efficiently Induces Apoptosis in Tumor Cells

Uwe Zangemeister-Wittke, Siân H. Leech, Robert A. Olie, A. Paula Simões-Wüst, Oliver Gautschi, Gerd H. Luedke, François Natt, Robert Häner, Pierre Martin, Jonathan Hall, Carlo M. Nalin, Rolf A. Stahel
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (6): 2547–2555.
Published: 01 June 2000
View articletitled, A Novel Bispecific Antisense Oligonucleotide Inhibiting Both bcl-2 and bcl-xL Expression Efficiently Induces Apoptosis in Tumor Cells
Open the PDF for A Novel Bispecific Antisense Oligonucleotide Inhibiting Both bcl-2 and bcl-xL Expression Efficiently Induces Apoptosis in Tumor Cells in another window